What is medication‑overuse headache and how is it managed?

Medication-Overuse Headache: Definition and Management

Medication-overuse headache (MOH) is a chronic headache occurring on ≥15 days per month for at least 3 months in patients with a pre-existing headache disorder, caused by regular overuse of acute headache medications—and the only effective treatment is withdrawal of the overused medication, preferably abruptly (except for opioids), combined with patient education. 1, 2

What is Medication-Overuse Headache?

MOH develops when patients with primary headaches (typically migraine) overuse acute medications, transforming episodic headache into chronic daily headache. The diagnostic thresholds vary by medication type 1:

• ≥15 days per month: NSAIDs, acetaminophen, combination analgesics
• ≥10 days per month: Triptans, ergotamines, opioids, combination medications

The prevalence is approximately 1-2% in the general population but substantially higher among patients with chronic migraine 3, 4. MOH accounts for roughly two-thirds of chronic daily headache cases in migraine patients 2.

Risk Factors to Assess

Evaluate these high-risk factors in order of relative impact 5:

1. Headache frequency ≥7 days/month (highest risk)
2. Migraine diagnosis
3. Frequent medication use: anxiolytics, analgesics (including opioids), sedative-hypnotics
4. Psychiatric comorbidities: anxiety or depression, especially with musculoskeletal or GI symptoms
5. Physical inactivity
6. Sick leave >2 weeks in past year
7. History of whiplash
8. Tobacco use

Female sex, inadequate acute treatment, and comorbid obesity also increase transformation risk 2.

Management Algorithm

Step 1: Patient Education (First-Line, Essential)

Education is the cornerstone and should be attempted first in all patients 2, 6. This is effective in 50-70% of cases 3.

Key educational points to cover 2, 7:

• The MOH concept: Explain how frequent medication use perpetuates and worsens headaches
• Specific thresholds: Clarify the frequency limits for their particular medications
• Withdrawal expectations: Warn that headaches will worsen for 2-10 days before improving 2
• Treatment plan: Establish clear agreement on withdrawal approach and follow-up
• Risk factors: Address modifiable factors (physical activity, comorbidities, triggers)

Step 2: Medication Withdrawal

If education alone fails, proceed to withdrawal—this is the necessary and only definitive remedy 2, 3.

Withdrawal method depends on medication class 2, 6:

• Abrupt withdrawal (preferred): For NSAIDs, triptans, ergotamines, simple analgesics
• Gradual tapering (required): For opioids, barbiturates, benzodiazepines, tranquilizers

Setting for withdrawal 6, 8:

• Outpatient: First-line for most patients with simple analgesic or triptan overuse
• Day hospital or inpatient: Reserve for opioid/barbiturate dependence, severe comorbidities, or failed outpatient attempts

Step 3: Preventive Therapy

Initiate preventive medication either simultaneously with withdrawal or upon re-emergence of the underlying headache pattern 2. The timing remains debated, but early initiation is generally favored 2.

For episodic migraine prevention 5:

• First-line: Candesartan, telmisartan (strong recommendation)
• First-line: Erenumab, fremanezumab, galcanezumab (CGRP antibodies—strong recommendation)
• Second-line: Topiramate, lisinopril, magnesium

For chronic migraine prevention 2:

• First-line: Topiramate (most cost-effective)
• Second-line: OnabotulinumtoxinA
• Second-line: CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab)

The CGRP antibodies show particular promise in MOH, potentially offering an alternative to extensive withdrawal programs in less complex patients 8.

Step 4: Bridging Therapy (Optional)

Consider short-term bridging medications to manage withdrawal symptoms 9:

• Antiemetics for nausea
• Short course of corticosteroids (controversial, limited evidence)
• Non-overused acute medications for severe breakthrough headaches

Step 5: Multidisciplinary Support

For complex cases or those with comorbidities, engage 6, 8:

• Behavioral psychology (cognitive-behavioral therapy)
• Physical therapy
• Stress management/relaxation techniques
• Treatment of psychiatric comorbidities (anxiety, depression)

Critical Management Pitfalls

Avoid these common errors:

1. Using opioids or butalbital for acute migraine treatment 1—these have the highest risk of MOH and dependency
2. Failing to warn patients about withdrawal worsening 2—this leads to treatment abandonment
3. Attempting slow tapering of non-addictive medications 2—abrupt withdrawal is more effective
4. Neglecting preventive therapy 2, 3—withdrawal alone has higher relapse rates
5. Inadequate follow-up 3, 8—relapse rates are 30-50% without structured monitoring

Follow-Up and Relapse Prevention

Schedule frequent follow-up visits 3, 8:

• Weekly or biweekly during first 2 months post-withdrawal
• Monthly for next 3-6 months
• Ongoing education about medication limits

Success rates: 50-70% overall, but lower (higher relapse) with opioid overuse 3. Relapse rates can be reduced through patient education and structured follow-up 3.

Prevention in At-Risk Patients

For patients not yet meeting MOH criteria but at risk 1:

• Counsel on frequency limits: <10 days/month for triptans, <15 days/month for NSAIDs
• Optimize acute treatment: Use combination therapy (triptan + NSAID) to reduce treatment frequency
• Consider preventive therapy early: If headaches occur ≥2 days/week or cause significant disability
• Address lifestyle factors: Hydration, regular meals, consistent sleep, aerobic exercise, stress management, weight loss if indicated 1